Page 65 - 2022_01-Haematologica-web

Effect of pre-existing anti-PEG antibodies on PEG-ASNase
J, Burke PW. Catalyzing improvements in ALL therapy with asparaginase. Blood Rev. 2017;31(5):328-338.
42. Benitez L, Perissinotti AJ, Santarossa M, Marini BL. Pharmacokinetic and clinical con- siderations for monitoring asparaginase activity levels during pegaspargase therapy. Pediatr Blood Cancer. 2015;62(6):1115.
43.Verma A, Chen K, Bender C, Gorney N, Leonard W, Barnette P. PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegas- pargase in the absence of asparaginase Erwinia chrysanthemi availability. Pediatr Hematol Oncol. 2019;36(5):277-286.
44. Marini BL, Brown J, Benitez L, et al. A single- center multidisciplinary approach to manag- ing the global Erwinia asparaginase short-
age. Leuk Lymphoma. 2019;60(12):2854-
2868.
45. Cooper SL, Young DJ, Bowen CJ, Arwood
NM, Poggi SG, Brown PA. Universal pre- medication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. Pediatr Blood Cancer. 2019;66(8):e27797.
46. Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol. 2014;32(34): 3874-3882.
47. Avramis VI, Panosyan EH. Pharmacokinetic/ pharmacodynamic relationships of asparagi- nase formulations: the past, the present and
recommendations for the future. Clin
Pharmacokinet. 2005;44 (4):367-393.
48. Chan WK, Lorenzi PL, Anishkin A, et al. The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells. Blood. 2014;123(23):
3596-3606.
49. Kloos RQH, Mathôt R, Pieters R, van der
Sluis IM. Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model. Haematologica. 2021;106(5):1254- 1261.
50. Lanvers-Kaminsky C, Niemann A, Eveslage M, et al. Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diag- nosed acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61(1):138-145.
haematologica | 2022; 107(1)
57